We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+23.18%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$830M
AUM Growth
+$42.8M
Cap. Flow
-$37.4M
Cap. Flow %
-4.51%
Top 10 Hldgs %
61.35%
Holding
46
New
10
Increased
9
Reduced
10
Closed
4

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$50.9M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$32M
3
ARRY
Array Biopharma Inc
ARRY
+$26M
4
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$18.6M
5
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$14.8M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$57.8M
2
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$44.5M
3
CBIO
Crescent Biopharma
CBIO
+$36.1M
4
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$23.5M
5
CTMX icon
CytomX Therapeutics
CTMX
+$22.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARRY
1
DELISTED
Array Biopharma Inc
ARRY
$111M 13.4%
8,686,498
+2,283,973
+36% +$26M
ANAB icon
2
AnaptysBio
ANAB
$1.63B
$59.9M 7.22%
594,397
-784,737
-57% -$57.8M
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$57.9M 6.98%
767,354
-240,000
-24% -$16.9M
XOMA
4
DELISTED
Xoma
XOMA
$53.5M 6.45%
1,502,800
– –
CNCE
5
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$51M 6.14%
1,969,789
-1,165,500
-37% -$23.5M
CYTK icon
6
Cytokinetics
CYTK
$10.9B
$46.6M 5.62%
5,721,888
+4,480,867
+361% +$50.9M
CCXI
7
DELISTED
ChemoCentryx, Inc.
CCXI
$45.1M 5.44%
7,587,416
– –
BLRX
8
BioLineRX
BLRX
$11.7M
$28.3M 3.42%
43,326
– –
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.73B
$28.3M 3.41%
+3,233,618
New +$32M
ARQL
10
DELISTED
Arqule Inc
ARQL
$27.1M 3.27%
16,436,912
+9,036,784
+122% +$11.7M
CTMX icon
11
CytomX Therapeutics
CTMX
$714M
$23.7M 2.86%
1,124,483
-1,106,415
-50% -$22.9M
CTIC
12
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$23M 2.78%
8,596,357
– –
KURA icon
13
Kura Oncology
KURA
$826M
$20.7M 2.5%
1,353,846
– –
INFI
14
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$19.8M 2.39%
9,766,508
+1,900,400
+24% +$3.94M
PVLA
15
Palvella Therapeutics
PVLA
$2.15B
$19.8M 2.39%
32,795
-4,537
-12% -$2.11M
OMED
16
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$17.5M 2.11%
+4,271,289
New +$18.6M
RGLS
17
DELISTED
Regulus Therapeutics
RGLS
$14.5M 1.75%
116,452
+8,542
+8% +$1.08M
ONCT
18
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$14.1M 1.7%
7,910
-7
-0.1% -$10.1K
PHXM
19
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$13.8M 1.66%
+62,500
New +$14.8M
VBIV
20
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
$13.2M 1.6%
+103,333
New +$12.7M
FWP
21
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$12.6M 1.52%
493,588
+285,714
+137% +$10M
SPRO icon
22
Spero Therapeutics
SPRO
$69.5M
$12.1M 1.46%
+1,029,185
New +$12.6M
CASC
23
DELISTED
Cascadian Therapeutics, Inc.
CASC
$11.6M 1.4%
3,133,224
– –
FSTX
24
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$11.1M 1.34%
205,869
+42,700
+26% +$2.54M
XENE icon
25
Xenon Pharmaceuticals
XENE
$6.2B
$10.1M 1.22%
3,588,830
– –
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2017 Portfolio in Review

As of Q4 2017, BVF Inc held 46 positions worth $830M, up 5.4% from $787M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc withdrew a net $37.4M in Q4 2017, closing 4 positions and reducing 10 holdings. Its most notable exit was Ironwood Pharmaceuticals, an estimated $44.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier.

Against the trend, BVF Inc opened a new position in Syndax Pharmaceuticals worth $28.3M.

  • BVF Inc's largest Q4 2017 buy was Syndax Pharmaceuticals: 3,233,618 shares worth $28.3M.
  • BVF Inc added most to Cytokinetics in Q4 2017, an estimated $50.9M increase.
  • BVF Inc's biggest Q4 2017 reduction was AnaptysBio, cutting an estimated $57.8M.
  • BVF Inc fully exited Ironwood Pharmaceuticals in Q4 2017, selling an estimated $44.5M.
  • BVF Inc's ten largest holdings make up 61% of its $830M portfolio in Q4 2017.
  • BVF Inc opened 10 new positions and closed 4 in Q4 2017.
  • BVF Inc's portfolio value rose 5.4% quarter-over-quarter to $830M.

Based on BVF Inc's 13F filing for Q4 2017, filed 14 Feb 2018.